Johnson Fistel probes Ultragenyx over alleged fiduciary breaches tied to setrusumab study

The law firm said shareholders who held Ultragenyx stock before Aug. 3, 2023 may seek governance reforms and the return of funds to the company at no cost.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.